Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : TM Bioscience Corp. tmc.v -- Ignore unavailable to you. Want to Upgrade?

To: Rhys Roberts who wrote (97)	1/27/1999 6:48:00 PM
From: Rhys Roberts	Read Replies (1) \| Respond to of 137

TM Bioscience retains investor relations services TORONTO, Jan. 25 /CNW/ - VSE - TMC Tm Bioscience announced today that it has signed an agreement with The Equicom Group Inc., to act as investor relations consultants for the Company. Terms of the agreement consist of a base monthly retainer of $5,000 for a period of two years. The Equicom Group provides financial communication services to Canadian companies specializing in technology and life sciences. The principals of Equicom are Barry Hildred, President, Cory Pala, Vice President and Jason Hogan, Vice President. The Company maintains its head office in Toronto, Ontario. Tm Bioscience is an emerging Canadian biotechnology company developing and commercializing proprietary DNA based technologies for application in biochips, diagnostics and genomic analysis. The Company offers pharmaceutical and biotechnology companies the ability to develop novel nucleic acid-based products for medical and research applications. Additional information about Tm Bioscience can be found at www.tmbioscience.com. Tm Bioscience trades on the Vancouver Stock Exchange under the symbol TMC and has approximately 69 million shares outstanding.